Heidrun Rexer

Prospective randomized double‐blind multicentre phase <scp>II</scp> study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: <scp>SUSE</scp> ( <scp>AUO‐AB</scp> 31/05)

S. Krege, Heidrun Rexer, F. vom Dorp et al. · British Journal of Urology · 2013 · 68 citations

Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05).

S. Krege, Heidrun Rexer, F. vom Dorp et al. · Journal of Clinical Oncology · 2010 · 27 citations

Pharmacotherapy, Metronomic Chemotherapy, Neuro-oncology +16

LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial

Carsten‐Henning Ohlmann, Michelle Jäschke, Peter Jaehnig et al. · Prostate Cancer and Prostatic Diseases · 2022 · 13 citations · Full text

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

Carsten‐Henning Ohlmann, Michelle Jäschke, Peter Jaehnig et al. · Trials · 2017 · 11 citations · Full text